Seeing Is Believing
Currently out of the existing stock ratings of Kennen Mackay, 129 are a BUY (66.15%), 65 are a HOLD (33.33%), 1 are a SELL (0.51%).
Analyst Kennen Mackay, currently employed carries an average stock price target met ratio of 53.25% that have a potential upside of 20.77% achieved within 140 days. Previously, Kennen Mackay worked at RBC.
Kennen Mackay’s has documented 378 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on VIRX, Viracta Therapeutics at 10-Nov-2023.
Analyst best performing recommendations are on XLRN (ACCELERON PHARMA).
The best stock recommendation documented was for SGEN (SEAGEN) at 2/1/2021. The price target of $186 was fulfilled within 4 days with a profit of $23.14 (14.21%) receiving and performance score of 35.52.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
15
$9.3 (163.16%)
15
17 days ago
0/4 (0%)
$10.05 (203.03%)
Buy
21
$15.3 (268.42%)
36
3 months 15 days ago
1/4 (25%)
$16.4 (356.52%)
61
Hold
6
$0.3 (5.26%)
5
1 years 9 months 17 days ago
2/3 (66.67%)
$1.85 (44.58%)
257
Buy
75
$70.79 (1681.47%)
50
3 years 9 months 20 days ago
2/3 (66.67%)
$45.92 (117.11%)
101
Buy
22
4 years 3 months 23 days ago
1/3 (33.33%)
$-59.25 (-72.92%)
820
What Year was the first public recommendation made by Kennen Mackay?